Hypertension in dialysis

被引:23
作者
Santos, SFF
Peixoto, AJ
机构
[1] Univ Estado Rio De Janeiro, Div Nephrol, Rio De Janeiro, RJ, Brazil
[2] Yale Univ, Sch Med, Nephrol Sect, New Haven, CT USA
[3] VA Connecticut Healthcare Syst, Hypertens Clin, West Haven, CT USA
关键词
cardiovascular disease; hemodialysis; hypertension; peritoneal dialysis;
D O I
10.1097/00041552-200503000-00005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Hypertension is highly prevalent in dialysis patients and may be important to the high cardiovascular mortality of this population. This review shows the current direction in dialysis-associated hypertension management. Recent findings Decreasing dialysate sodium concentration based on pre-hemodialysis plasma sodium concentration may have an additive effect in controlling hypertension. Sympathetic nervous system overactivity is an important feature of end-stage renal disease; a new amine oxidase, renalase, may be relevant to the pathogenesis of hypertension in this population. Similarly, drugs that block the sympathetic nervous system are uniformly protective in dialysis patients. Daily dialysis (short or long) results in better blood pressure control, and the mechanisms resulting in this effect are increasingly better understood. Summary Long-term control of hypertension is necessary in dialysis patients. The better understanding of the dialysis-associated hypertension pathogenesis has impact on the dialysis prescription and antihypertensive drug choices.
引用
收藏
页码:111 / 118
页数:8
相关论文
共 79 条
[1]   Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States [J].
Agarwal, R ;
Nissenson, AR ;
Batlle, D ;
Coyne, DW ;
Trout, JR ;
Warnock, DG .
AMERICAN JOURNAL OF MEDICINE, 2003, 115 (04) :291-297
[2]   Assessment of blood pressure in hemodialysis patients [J].
Agarwal, R .
SEMINARS IN DIALYSIS, 2002, 15 (05) :299-304
[3]   Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses [J].
Agarwal, R ;
Lewis, R ;
Davis, JL ;
Becker, B .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (06) :1245-1250
[4]   Prediction of hypertension in chronic hemodialysis patients [J].
Agarwal, R ;
Lewis, RR .
KIDNEY INTERNATIONAL, 2001, 60 (05) :1982-1989
[6]   Supervised atenolol therapy in the management of hemodialysis hypertension [J].
Agarwal, R .
KIDNEY INTERNATIONAL, 1999, 55 (04) :1528-1535
[7]   Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients [J].
Amar, J ;
Vernier, I ;
Rossignol, E ;
Bongard, V ;
Arnaud, C ;
Conte, JJ ;
Salvador, M ;
Chamontin, B .
KIDNEY INTERNATIONAL, 2000, 57 (06) :2485-2491
[8]   Endogenous ouabain: Role in the pathogenesis of hypertension [J].
Blaustein, MP .
KIDNEY INTERNATIONAL, 1996, 49 (06) :1748-1753
[9]   Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects [J].
Cannella, G ;
Paoletti, E ;
Delfino, R ;
Peloso, G ;
Rolla, D ;
Molinari, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30 (05) :659-664
[10]   Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients [J].
Cannella, G ;
Paoletti, E ;
Ravera, G ;
Cassottana, P ;
Araghi, P ;
Mulas, D ;
Peloso, G ;
Delfino, R ;
Messa, P .
KIDNEY INTERNATIONAL, 2000, 58 (01) :260-268